CDER’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.
Similar Posts
FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication
On August 22, 2025,the US FDA’s Center for Biologics Evaluation and Research has suspended the biologics license for Valneva Austria GmbH’s Ixchiq (Chikungunya Vaccine, Live). This vaccine was initially approved by FDA under the accelerated approval pathway in November of 2023 for the prevention ofQuestions and Answers on the iPLEDGE REMS
Questions and Answers on the iPLEDGE REMSRevitalize Energy, Inc. – 712417 – 07/09/2025
Unapproved New Drugs/MisbrandedMedWatch: The FDA Safety Information and Adverse Event Reporting Program
MedWatch is made up of voluntary and mandatory reporting on prescription medicines, over-the-counter medicines, non-vaccine biologicals, medical devices, special nutritional products, cosmetics and non-prescription human drug products marketed without an approved application.www.plakini-pharma.com – 705185 – 07/16/2025
Unapproved New Drugs/MisbrandedAdvancing Generic Drug Development: Translating Science to Approval 2025 – 10/07/2025
Join us for the 2025 Advancing Generic Drug Development Workshop! FDA experts will demonstrate the FDA’s Generic Drug User Fee Amendments (GDUFA) Science and Research Program’s transformative impact on generic drug development, regulation, and approval.